HC Wainwright Analysts Give Urogen Pharma (NASDAQ:URGN) a $75.00 Price Target

Urogen Pharma (NASDAQ:URGN) received a $75.00 price objective from stock analysts at HC Wainwright in a report released on Monday, TipRanks reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective would indicate a potential upside of 243.88% from the stock’s current price.

Several other analysts have also recently weighed in on URGN. Stifel Nicolaus reaffirmed a “buy” rating and set a $61.00 price objective on shares of Urogen Pharma in a research report on Tuesday, September 24th. ValuEngine raised Urogen Pharma from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Cowen reaffirmed a “buy” rating on shares of Urogen Pharma in a research report on Tuesday, September 24th. Finally, Zacks Investment Research cut Urogen Pharma from a “hold” rating to a “sell” rating in a research report on Saturday. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company. Urogen Pharma currently has a consensus rating of “Buy” and a consensus price target of $56.25.

Shares of NASDAQ URGN traded up $0.03 during trading hours on Monday, hitting $21.81. The company’s stock had a trading volume of 111,741 shares, compared to its average volume of 208,093. The stock has a market cap of $463.49 million, a price-to-earnings ratio of -4.54 and a beta of 1.14. Urogen Pharma has a 12 month low of $20.72 and a 12 month high of $55.49. The business has a 50-day simple moving average of $27.92 and a 200-day simple moving average of $33.32.

Urogen Pharma (NASDAQ:URGN) last posted its earnings results on Friday, August 9th. The company reported ($1.08) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.20) by $0.12. The business had revenue of $0.02 million during the quarter. On average, equities research analysts anticipate that Urogen Pharma will post -4.95 earnings per share for the current fiscal year.

In other news, CFO Peter P. Pfreundschuh sold 1,416 shares of Urogen Pharma stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $33.07, for a total transaction of $46,827.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 10.50% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. United Services Automobile Association lifted its holdings in shares of Urogen Pharma by 0.9% during the second quarter. United Services Automobile Association now owns 50,605 shares of the company’s stock valued at $1,819,000 after purchasing an additional 470 shares during the last quarter. Rhumbline Advisers raised its holdings in Urogen Pharma by 4.4% in the 3rd quarter. Rhumbline Advisers now owns 22,010 shares of the company’s stock worth $524,000 after acquiring an additional 931 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. raised its holdings in Urogen Pharma by 50.0% in the 2nd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 3,000 shares of the company’s stock worth $108,000 after acquiring an additional 1,000 shares during the last quarter. Altshuler Shaham Ltd grew its position in shares of Urogen Pharma by 4.8% during the 2nd quarter. Altshuler Shaham Ltd now owns 25,892 shares of the company’s stock valued at $931,000 after acquiring an additional 1,194 shares during the period. Finally, Van ECK Associates Corp grew its position in shares of Urogen Pharma by 30.1% during the 2nd quarter. Van ECK Associates Corp now owns 5,813 shares of the company’s stock valued at $209,000 after acquiring an additional 1,345 shares during the period. Hedge funds and other institutional investors own 70.31% of the company’s stock.

About Urogen Pharma

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. The company's lead product candidates, UGN-101 and UGN-102 are proprietary formulations of the chemotherapy drug mitomycin, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.

Further Reading: Percentage Decliners

Analyst Recommendations for Urogen Pharma (NASDAQ:URGN)

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.